



## 2022 Summer Symposium and Reception

---

**Saturday, June 4, 2022, 5:00 pm – 10:00 pm**

The Metropolitan in Willis Tower  
233 South Wacker Drive, 66th Floor  
Chicago, Illinois 60606

## Chinese American Hematologist & Oncologist Network

## 美国华裔血液与肿瘤专家协会

### Conference Chairs

**Bo Zhao, MD**

Virginia Oncology Associates

**Chong-xian Pan, MD, PhD**

Harvard Medical School



## SPONSORS & EXHIBITORS

### 2022 Corporate Partners

---



### Bronze Sponsor

---



### Exhibitors

---

AVEO Oncology

Servier

Sobi

**CANCER HAS  
NO BORDERS.  
NEITHER  
DO WE**

**Our mission** is patients first through science and affordability. To help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation.

**8,000+**

employees  
(as of January 2022)

**30+**

filed or potentially registration  
enabling trials ongoing, **95+** studies  
in **40+** geographies

**~50**

commercial or clinical  
stage assets

**30**

offices on  
**5** continents

**20+**

filings accepted for **10** medicines in  
over **50** geographies, including 2<sup>nd</sup>  
drug in U.S. and first in E.U.

**9**

approved medicines,  
including **1** in the US

**Website:**  
[BeiGene.com](http://BeiGene.com)

**Twitter:**  
[@BeiGeneGlobal](https://twitter.com/BeiGeneGlobal)

**LinkedIn:**  
[linkedin.com/company/beigene](https://linkedin.com/company/beigene)

## CONTENTS

Event Sponsors	page 1
About CAHON	page 3
Upcoming CAHON Events Program	page 5
CAHON Young Investigator Awards	page 7
About our Speakers	page 8



## ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

## THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

## CAHON MEMBERSHIP

Apply to become a CAHON Membership at [cahon.org/membership](http://cahon.org/membership)

### Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

## MEMBERSHIP CATEGORIES

Regular/Active Membership

Associate Membership

Allied Membership

Visit [cahon.org/membership](http://cahon.org/membership) for more information on membership.



Nasopharyngeal carcinoma (NPC):

# FACING THE SURVIVAL FACTS

HEAD AND NECK CANCERS  
**1-YEAR  
PROGRESSION-FREE  
SURVIVAL**

**20%**

R/M NASOPHARYNGEAL<sup>\*</sup>

METASTATIC  
OROPHARYNGEAL<sup>‡†</sup>

**76%** **39%**  
HPV+ HPV-

**91%** STAGE IV  
LARYNGEAL<sup>‡‡</sup>

SEE THE  
**NPC**  
**FACTS**



[NPCFacts.com/summer](https://NPCFacts.com/summer)

**Nasopharyngeal carcinoma (NPC)** is a distinct cancer with a unique etiology and prognosis. Progression-free survival and overall survival data show poor outcomes in recurrent/metastatic disease, and limited effective treatment options highlight an unmet need in this area.

HPV = human papillomavirus, R/M = recurrent/metastatic.

<sup>\*</sup>Results from a multicenter, randomized, open-label phase 3 trial of patients with recurrent or metastatic nasopharyngeal carcinoma (N=362).

<sup>†</sup>Results from a retrospective analysis of patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer (N=108).

<sup>‡</sup>Results from a retrospective study of patients with laryngeal squamous cell carcinoma (N=211).

**References:** 1. Zhang L, et al. *Lancet*. 2016;388:1883-1892. 2. Guo T, et al. *Cancer*. 2015;121:1977-1984. 3. Zhang Q, et al. *Front Oncol*. 11:606010.



© 2022 Coherus BioSciences, Inc.  
All rights reserved. 0422-10-P165

## Save the Dates!

### 2022 COMMUNITY ONCOLOGY FORUM (COF)

July 30, 2022  
Sheraton Grand  
Seattle, Washington

CAHON's Community Oncology Forum is a half-day program that is geared towards practicing oncologists. Specifically, this program offers expert perspectives and practical insights into the use of immunotherapy and targeted treatments in cancer care with focuses on head and neck cancer, breast cancer, lymphoma and leukemia.

### 2022 CHINA CANCER IMMUNOTHERAPY WORKSHOP

September 1-2, 2022 (USA)  
September 2-3, 2022 (China)  
In Person: Beijing, China  
Virtual: United States and Europe

Since 2015, CAHON has partnered with the China National Medical Products Administration (NMPA) and the Tsinghua University College of Medicine to organize this important event. This workshop hosts speakers from these major regulatory agencies, the US FDA, European Medicines Agency (EMA) and additional experts in the immuno-oncology field. The meeting will take place in-person in Beijing, China and virtually for participants outside of China.

### 2022 NEW YORK ONCOLOGY FORUM (NYOF)

October 8-9, 2022  
Westchester Marriott  
Tarrytown, NY

The CAHON annual New York Oncology Forum (NYOF) is a one and a half day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. 2022 will mark the 9th year for this annual event and it draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in the hematology and oncology.

### 2022 WINTER SYMPOSIUM AND RECEPTION

December 10, 2022 (tentative)  
New Orleans, LA

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments with an emphasis on hematological malignancies, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.





## LILLY FOR BETTER

The human race has always been curious, hopeful and resilient. Discovery is our purpose on this planet. It's our calling and the spirit that's defined Lilly since day one. After more than a century and nearly 100 medicines and countless innovations, we're still searching for the next great discovery that will make life better for people around the world.

[lilly.com](https://www.lilly.com)

2020 CA Approved for External Use PRINTED IN USA ©2020, Eli Lilly and Company. ALL RIGHTS RESERVED.

*Lilly*



# Program

---

## 6:30 – 6:45 pm CAHON Presentations

### Opening Remarks and Introduction of VIP Guests

Chong-xian Pan, MD, PhD, *President*

Wenru Song, MD, PhD, *Board Chair*

### Introduction of new Board Chair, RuiRong Yuan, MD, PhD, Outgoing Board Members and New Board Members

Wenru Song, MD, PhD, *Board Chair*

### CAHON Presidential Address

Chong-xian Pan, MD, PhD, *President*, Bo Zhao, MD, *President Elect*

### Updates on CAHON Journals

Delong Liu, MD, PhD, *Editor-in-Chief, Journal of Hematology & Oncology*

## 6:45 – 7:00 pm Young Investigator Awards Ceremony

Tian Zhang, MD, MHS, J Christine Ye, MD, Wanqing Iris Zhi, MD, PhD

*CAHON 2020-2022 Academic Committee*



Every year, several Young Investigator Awards are awarded to CAHON early career or physician-in-training members in hopes of fostering growth and achievement. The award is based on the scientific merit of abstracts accepted to either the American Society of Clinical Oncology (ASCO) Annual Meeting or the American Society of Hematology (ASH).

*Congratulations to the Young Investigator Award winners!*

## 7:00 – 8:15 Scientific Presentations

### 7:00 – 7:15 Emerging Treatment Options for Gastrointestinal Cancers

Zhaohui Jin, MD, *Mayo Clinic*

### 7:15 – 7:30 New Advances for the Treatment of Melanoma Cancers

Yiyi Yan, MD, PhD, *Mayo Clinic*

### 7:30 – 7:45 Update of Genitourinary Malignancies

Tian Zhang, MD, MHS, *UT Southwestern Medical Center*

### 7:45 – 8:00 Panel Discussion

### 8:00 – 8:15 Closing Remarks

Bo Zhao, MD, *President Elect*

Ruirong Yuan, MD, PhD, *Board Chair Elect*

## 8:15 – 10:00 pm Social Gathering and Visit Exhibit Booths

### Organizing Committee

Bo Zhao, MD, *Virginia Oncology Associates*

Tian Zhang, MD, MHS, *UT Southwestern Medical Center*

J Christine Ye, MD, *University of Michigan*

Iris Zhi, MD, PhD, *Memorial Sloan Kettering Cancer Center*

Chong-xian Pan, MD, PhD, *Harvard Medical School*

Wenru Song, MD, PhD, *Kira Pharma*

J Christine Ye, MD, *University of Michigan*

## Speakers



**Dr. Yiyi Yan** is an Assistant Professor in the Division of Medical Oncology, College of Medicine at Mayo Clinic Rochester. Dr. Yan received her MD at Shanghai Second Medical University. She then received M.S. and Ph.D degrees in 2006 and 2010, respectively, in molecular biology and molecular genetics, at The University of Texas MD Anderson Cancer Center. She completed her residency in Internal Medicine in York, Pennsylvania, and then completed her Medical Oncology-Hematology fellowship training at Mayo Clinic Rochester.

Her clinical expertise includes immunotherapy, targeted therapy and combination therapy for patients with advanced melanoma and cutaneous malignancies. Dr. Yan currently serves as Chair for Melanoma and Cutaneous Malignancy Tumor Group at Mayo Clinic Rochester. Dr. Yan is a NCI-funded researcher, and her primary research interests focus on translational research in tumor immunology and cancer immunotherapy as well as clinical trial development, aiming to improve clinical outcome of patients with advanced cancer.



**Dr. Tian Zhang** received her MD from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School and completed post-graduate training at Duke University, where she remained on faculty until 2021. She is now Associate Professor within the

Division of Hematology and Oncology and Department of Internal Medicine at University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center. She leads the multi-disease and precision oncology program within the cancer center. Clinically she specializes in genitourinary malignancies. She participates actively in the cooperative group setting and currently serves as co-chair of the NCI GU Steering Committee Renal Task Force. She is a clinical researcher focused on improving novel therapies and biomarkers for patients with renal, prostate, and urothelial cancers.



**Dr. Zhaohui Jin** received his MD at Peking Union Medical College in Beijing, China then worked in the Department of hematology at the Sixth People's Hospital of Shanghai. Dr. Jin came to the United States working as a research fellow at the Shands cancer center, University of Florida in 2002. Dr. Jin moved to Boston and worked as an instructor at Harvard medical school between 2005-2010. Subsequently Dr. Jin completed residency training in New Jersey followed by hematology/oncology fellowship in Iowa. Dr. Jin completed his advanced GI oncology fellowship at Mayo Clinic in 2017. He worked as a clinical assistant professor at University of Illinois Urbana-Champaign (UIUC) for about a year. Dr. Jin then returned to Mayo Clinic in 2/2019 and works as a GI medical oncologist at the Department of Medical oncology.



**INNOCARE**  
诺诚健华

### Orelabrutinib – Potential Best-in-Class BTK Inhibitor

- **Orelabrutinib demonstrates compelling efficacy**
  - In 80 patients with R/R CLL, at median follow-up of 32.3 months, ORR was 93.8%, CR was 24%, CRi was 2%. mDoR NR
  - In 99 patients with R/R MCL, at median follow-up of 23.8 months, ORR was 88%, CR was 37%, mDoR was 26-mo
- **Orelabrutinib shows class leading safety and tolerability in patients with various b-cell malignancies**
  - No case of  $\geq 3$  Grade 3 A-fib, rare case of major bleeding/severe hypertension/diarrhea
  - Most common AE are Grade 1-2, occurring during the early course of treatment
  - 5% of patients discontinued treatment due to AE, 2% were treatment related
- **Orelabrutinib has demonstrated similar efficacy and safety profile in US patients**
- **Orelabrutinib has been granted Breakthrough Therapy Designation for r/r MCL indication by the FDA**
- **We are recruiting BTKi treatment naïve r/r MCL patients for our US registration study**





**Chinese American Hematologist and Oncologist Network (CAHON)**  
555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA  
Phone: 1 414-918-9890 • Fax: 1 414-276-3349